Month: <span>August 2020</span>

PharmaShots Webinar: Deal And Venture Trends Through The First Half

On September 2, 2020, Octavus Consulting and DealForma will present their most recent data and trends on dealmaking across biopharma, device, diagnostics, and digital health. Healthcare and life sciences deal and venture activity through August 2020 has not slowed down despite the challenges thrown at business leaders globally. We will review recent trends covering the […]Read More

Ionis to Acquire Remaining Stake in Akcea Therapeutics for $18.5/share

Shots: Ionis will acquire all the outstanding shares of Akcea common stock it does not already own, ~24%, for $18.15/share in cash, making a total deal value as $500M. The transaction is expected to be completed in Q4’20 Following the completion of the acquisition, Ionis will get access to Akcea’s rich pipeline and commercial products […]Read More

Mylan and Biocon Launch Semglee (insulin glargine injection) as Vials

Shots: The companies have launched Semglee (insulin glargine injection) in a vial and pre-filled pen at WAC of $147.98/ package of (5) 3ml pens and $98.65/ 10ml vial, representing the lowest WAC for any long-acting insulin glargine The US FDA has approved Semglee for the same indications as to its reference product Sanofi’s Lantus, thus […]Read More

Cadila Launches Cadalimab (biosimilar, adalimumab) in India

Shots: Cadila has launched the adalimumab biosimilar under the brand name Cadalimab, referencing AbbVie’s Humira which is used to treat RA,PsA, AS and psoriasis The launch strengthens Cadila’s biosimilar portfolio as Cadalimab is the fourth biosimilar launched in the last 2mos. following Bevaro, Ritucad and NuPTH for cancer and osteoporosis Cadalimab is available in 40mg/0.8ml, […]Read More

World’s First App-Based Nicotine Addiction Treatment Receives the MHLW’s Approval

Shots: On Aug 21, 2020, CureApp receives MHLW’s approval for the manufacturing and sale of Asia’s first therapeutics app, the “CureApp SC Nicotine Addiction Treatment App and CO Checker’’. The company plans to receive insurance reimbursement and release CureApp SC in FY2020 CureApp SC is a prescription medical device designed to aid patients receiving outpatient […]Read More

Novartis Reports Results of LNP023 in P-II Study for Paroxysmal

Shots: The P-II study involves assessing of LNP023 in PNH patients with active hemolysis despite treatment with eculizumab Results: improvements in hematological response and biomarkers of disease activity; 70% discontinued eculizumab and remained on LNP023 as monothx., retaining Hb levels with no changes in biomarkers of disease activity and with no signs or symptoms of […]Read More

PharmaShots Weekly Snapshot (Aug 24 -28, 2020)

1. Taysha Gene Therapies’ TSHA-101 Receives the US FDA’s Orphan Drug Designation and Rare Pediatric Disease Designation for GM2 Gangliosidosis Published: Aug 27, 2020 | Tags:  Taysha Gene Therapies, TSHA-101, Receives, US, FDA, Orphan Drug Designation, Rare Pediatric Disease Designation, GM2 Gangliosidosis 2. Bayer Reports the NDA Submission to NMPA for Vericiguat to Treat Chronic […]Read More